A Retrospective Observational Study to Determine Baseline Characteristics and Early Prescribing Patterns for Patients Receiving Alirocumab in UK Clinical Practice

BACKGROUND: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) and has been previously shown, in the phase III ODYSSEY clinical trial program, to provide significant lowering of low-density lipoprotein cholesterol (LDL-C) and reduction in risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Reynolds, Tim, Carey, Peter, George, Jacob, Konidaris, Gerasimos, Narayanan, Deepa, Ramachandran, Sudarshan, Saunders, Luke, Viljoen, Adie, Ferns, Gordon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879683/
https://www.ncbi.nlm.nih.gov/pubmed/31741198
http://dx.doi.org/10.1007/s40801-019-00166-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879683/
https://www.ncbi.nlm.nih.gov/pubmed/31741198
http://dx.doi.org/10.1007/s40801-019-00166-7

Ejemplares similares